Recently, there is growing interest in promising Nrf2 activators because many physiological studies showed the Nrf2 activation alleviated pathological conditions, including chronic kidney disease, pulmonary hypertension, neurodegenerative disorder, and cancer [14,15]. This evidence concerns the gene NFE2L2 and pulmonary arterial hypertension.